Why Nuwellis Stock Is Climbing
Why Nuwellis Stock Is Climbing
"We are thrilled to introduce QUELIMMUNE to critically ill pediatric patients in need. This marks a significant step forward in Nuwellis' mission to execute our pediatric business development strategy. By partnering with SeaStar Medical, we are committed to bringing this groundbreaking therapy to U.S. healthcare providers, offering new hope to children suffering from severe immune system reactions," said Nuwellis, Inc. (NASDAQ:NUWE) shares are trading higher Monday after the company announced Friday that the first pediatric patient has been treated with the newly launched Quelimmune therapy in a commercial setting.
Nuwellis，Inc.（納斯達克：NUWE）股票週一交易上漲，此前公司宣佈，週五第一個兒科患者在商業環境下接受新推出的Quelimmune療法治療。
The Details:
細節：
Quelimmune is a novel therapy designed to treat pediatric patients suffering from acute kidney injury (AKI) with sepsis or a septic condition and requiring kidney replacement therapy (KRT) manufactured for SeaStar Medical Holding Corp (NASDAQ:ICU) and exclusively licensed and distributed in U.S. pediatric hospitals by Nuwellis.
Quelimmune是一種新型治療急性腎損傷（AKI）伴有膿毒症或膿毒症狀態並需要腎臟替代治療（KRT）的小兒患者的療法，由SeaStar Medical Holding Corp（納斯達克：ICU）製造，並由Nuwellis在美國小兒醫院獨家許可和分銷。
"We are thrilled to introduce QUELIMMUNE to critically ill pediatric patients in need. This marks a significant step forward in Nuwellis' mission to execute our pediatric business development strategy. By partnering with SeaStar Medical, we are committed to bringing this groundbreaking therapy to U.S. healthcare providers, offering new hope to children suffering from severe immune system reactions," said Nestor Jaramillo, CEO of Nuwellis.
“我們很高興將QUELIMMUNE介紹給需要的重症小兒患者。這是Nuwellis執行我們的小兒業務發展戰略邁出的重要一步。通過與SeaStar Medical合作，我們致力於將這種開創性的療法帶給美國的醫療機構，爲患有嚴重免疫系統反應的兒童提供新的希望，”Nuwellis的CEO Nestor Jaramillo說。
Roth MKM analyst Jonathan Aschoff initiated coverage on Nuwellis with a Buy rating and a $17 price target Monday. According to data from Benzinga Pro, Nuwellis shares are trading below the stock's 50-day moving average of $6.30 and near its 52-week low of $2.19.
Roth MKm的分析師Jonathan Aschoff週一對Nuwellis進行了買入評級，並給出了17美元的目標價。根據Benzinga Pro的數據，Nuwellis的股票價格低於6.30美元的50日移動平均線，接近其52周低點2.19美元。
How To Buy NUWE Stock:
如何購買NUWE股票：
By now you're likely curious about how to participate in the market for Nuwellis – be it to purchase shares, or even attempt to bet against the company.
現在你可能好奇如何參與Nuwellis的市場，無論是購買股票，甚至試圖對該公司進行做空。
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy 'fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
購買股票通常是通過證券帳戶進行的。您可以在這裏找到可能的交易平台列表。許多交易平台將允許您購買“碎股”，這樣可以購買部分股票而非整張股票。例如，有些股票，如伯克希爾-哈撒韋公司或亞馬遜公司，可能需要數千美元才能持有一股。但是，如果您只想投資其中一小部分，券商將允許您這樣做。
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to 'go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
如果您想押注股票下跌，流程就更爲複雜了。您需要訪問期權交易平台，或者找一家券商讓您通過借出股票進行“開空”操作（借股出售）。您可以在該資源中了解到賣空股票的過程。否則，如果您的券商允許您交易期權，您可以在當前股票交易價以上的執行價上購買看跌期權或者賣出看漲期權 - 無論哪種情況都可以讓您從股票價格下跌中獲利。
NUWE Price Action: According to Benzinga Pro, Nuwellis shares are up 20.8% at $2.90 at the time of publication Monday.
NUWE的價格變動：根據Benzinga Pro的數據，在週一發表時，Nuwellis的股票價格上漲了20.8%，報2.90美元。
Read Also:
閱讀更多：
- Carbon Revolution Stock Races On Chevrolet Corvette ZR1 Wheels
- 碳革命股票以雪佛蘭Corvette ZR1車輪衝刺
Image: Unsplash
圖片：Unsplash
